Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44381   clinical trials with a EudraCT protocol, of which   7393   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
    Select Country:
    		 Select Age Range:
    Select Trial Status:
    		 Select Trial Phase:
    Select Gender:
    Select Date Range:
    to
    Select Rare Disease:
    IMP with orphan designation in the indication
    Orphan Designation Number:
    Results Status:
    Clear advanced search filters
     
    10,987 result(s) found. Displaying page 413 of 550.
    «« First « Previous 409  410  411  412  413  414  415  416  417  Next» Last»»
    EudraCT Number: 2017-002423-19 Sponsor Protocol Number: BGB-A317-301 Start Date*: 2018-08-24
    Sponsor Name:BeiGene, Ltd.
    Full Title: A Randomized, Open-label, Multicenter Phase 3 Study to Compare the Efficacy and Safety of BGB-A317 versus Sorafenib as First-Line Treatment in Patients with Unresectable Hepatocellular Carcinoma
    Medical condition: Unresectable Hepatocellular Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10019828 Hepatocellular carcinoma non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) CZ (Completed) FR (Completed) ES (Ongoing) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-003191-23 Sponsor Protocol Number: ANZUP1303 Start Date*: 2014-11-07
    Sponsor Name:Cancer Trials Ireland
    Full Title: Randomised phase 3 trial of enzalutamide in androgen deprivation therapy with radiation therapy for high risk, clinically localised, prostate cancer: ENZARAD
    Medical condition: Localised prostate cancer at high risk of recurrence
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IE (Trial now transitioned) GB (GB - no longer in EU/EEA) BE (Completed) AT (Trial now transitioned) ES (Ongoing) SI (Completed) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-004118-16 Sponsor Protocol Number: MK-7339-010 Start Date*: 2019-04-15
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: A Phase 3, Randomized Open-label Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castrationresistant Prostate Cancer (mCRPC...
    Medical condition: Metastatic Castration resistant Prostate Cancer (mCRPC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10076506 Castration-resistant prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Completed) GB (GB - no longer in EU/EEA) FR (Completed) ES (Completed) IE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-001718-13 Sponsor Protocol Number: MP18 Start Date*: 2019-10-18
    Sponsor Name:MAPS Europe B.V.
    Full Title: An Open- Label, Phase 2, Multicenter Feasibility Study if Manualized MDMA-Assisted Psychotherapy with an fMRI sub-study Assessing Changes in Brain Activity in Subjects with Posttraumatic Stress Dis...
    Medical condition: post-traumatic stress disorder (PTSD)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) CZ (Completed) NO (Completed) DE (Completed) GB (GB - no longer in EU/EEA) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-004008-20 Sponsor Protocol Number: IPI-145-06 Start Date*: 2014-01-13
    Sponsor Name:Verastem, Inc.
    Full Title: A Phase 2 Study of IPI-145 in Subjects with Refractory Indolent Non-Hodgkin Lymphoma.
    Medical condition: Refractory Indolent Non-Hodgkin Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10029627 Non-Hodgkin's lymphoma unspecified histology intermediate grade refractory LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IT (Completed) HU (Completed) CZ (Completed) ES (Completed) BE (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2019-001562-15 Sponsor Protocol Number: CAAA601A22301 Start Date*: 2019-11-15
    Sponsor Name:Advanced Accelerator Applications SA
    Full Title: This is a multicenter, stratified, randomized, open-label comparator-controlled, Phase III study in patients with somatostatin receptor positive, well-differentiated G2 and G3, advanced GEP NETs, d...
    Medical condition: Patients with somatostatin receptor positive, well-differentiated G2 and G3, advanced GEP NETs
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052399 Neuroendocrine tumour PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10077559 Gastroenteropancreatic neuroendocrine tumour disease PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10077560 Gastroenteropancreatic neuroendocrine tumor disease LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) GB (GB - no longer in EU/EEA) DE (Ongoing) NL (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-000762-11 Sponsor Protocol Number: 62113-55115 Start Date*: 2014-10-20
    Sponsor Name:European Organisation for Research and Treatment of Cancer (EORTC)
    Full Title: A randomized double-blind phase II study evaluating the role of maintenance therapy with cabozantinib in High Grade Undifferentiated Uterine Sarcoma (HGUS) after stabilization or response to doxoru...
    Medical condition: High Grade Undifferentiated Uterine Sarcoma (HGUS)
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10046821 Uterine sarcoma NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) IT (Completed) ES (Completed) DE (Completed) GB (GB - no longer in EU/EEA) NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-005476-33 Sponsor Protocol Number: I4C-MC-JTBB Start Date*: 2013-08-27
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized, Controlled Phase 2 Study Evaluating LY2875358 plus Erlotinib versus Erlotinib as First-Line Treatment in Metastatic Non–Small Cell Lung Cancer Patients with Activating EGFR Mutations ...
    Medical condition: Non-Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) GB (GB - no longer in EU/EEA) NL (Ongoing) IT (Completed) FR (Completed) ES (Ongoing) DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-000145-39 Sponsor Protocol Number: AC-065A203 Start Date*: 2018-10-22
    Sponsor Name:Actelion Pharmaceuticals Ltd
    Full Title: A prospective, multicenter, open-label, single-arm, Phase 2 study to investigate the safety, tolerability and pharmacokinetics of selexipag in children with pulmonary arterial hypertension
    Medical condition: Pulmonary arterial hypertension
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10064911 Pulmonary arterial hypertension PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Trial now transitioned) DE (Trial now transitioned) HU (Trial now transitioned) PL (Completed) Outside EU/EEA BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-003673-10 Sponsor Protocol Number: AV003 Start Date*: Information not available in EudraCT
    Sponsor Name:Bond Avillion 2 Development LP
    Full Title: A Long-term, Randomized, Double-blind, Multicenter, Parallel-group, Phase III Study Evaluating the Efficacy and Safety of PT027 Compared to PT007 Administered as Needed in Response to Symptoms in S...
    Medical condition: Moderate to severe asthma
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10015575 Exacerbation of asthma LLT
    21.0 100000004855 10003561 Asthma, unspecified LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) GB (GB - no longer in EU/EEA) SK (Completed) ES (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-003503-39 Sponsor Protocol Number: ABR54654 Start Date*: 2016-07-27
    Sponsor Name:University Medical Center Utrecht
    Full Title: Placebo-controlled Trial in Subjects at Ultra-high Risk for Psychosis With Omega-3 Fatty Acids in Europe
    Medical condition: Individuals at Ultra High Risk for Psychosis
    Disease:
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed) AT (Completed) IT (Completed) ES (Ongoing) DE (Completed) GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2015-003594-14 Sponsor Protocol Number: KCP-330-020 Start Date*: 2018-07-03
    Sponsor Name:Karyopharm Therapeutics, Inc.
    Full Title: A Phase 2-3 Multicenter, Randomized, Double-blind Study of Selinexor (KPT-330) versus Placebo in Patients with Advanced Unresectable Dedifferentiated Liposarcoma (DDLS)
    Medical condition: Dedifferentiated Liposarcoma (DDLS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073135 Dedifferentiated liposarcoma PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) FR (Completed) ES (Completed) SE (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-002304-41 Sponsor Protocol Number: RIS-SCH-4045 Start Date*: 2005-09-23
    Sponsor Name:Janssen-Cilag EMEA Medical Affairs
    Full Title: Early versus late initiation of treatment with Risperdal Consta in subjects with schizophrenia or schizoaffective disorder after an acute episode
    Medical condition: Schizophrenia or schizoaffective disorder.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed) DK (Completed) FI (Completed) GB (Completed) SI (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-003104-42 Sponsor Protocol Number: NSR-CHM-OS2(273CH201) Start Date*: 2018-01-05
    Sponsor Name:NightstaRx Ltd (A Biogen Company)
    Full Title: A Long-term Follow-up Study to Evaluate the Safety and Efficacy of Retinal Gene Therapy in Subjects with Choroideremia Previously Treated with Adeno-Associated Viral Vector Encoding Rab Escort Prot...
    Medical condition: Choroideremia (CHM) X-Linked Retinitis Pigmentosa (XLRP)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004853 10008791 Choroideremia LLT
    20.0 10010331 - Congenital, familial and genetic disorders 10038914 Retinitis pigmentosa PT
    Population Age: Adults Gender: Male
    Trial protocol: DE (Trial now transitioned) GB (GB - no longer in EU/EEA) FI (Completed) FR (Trial now transitioned) DK (Completed) NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-005177-29 Sponsor Protocol Number: EORTC 26052-22053 Start Date*: 2006-11-10
    Sponsor Name:EORTC
    Full Title: Phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastoma
    Medical condition: Patients with Glioblastoma Multiforme
    Disease: Version SOC Term Classification Code Term Level
    8.1 10018337 Glioblastoma multiforme LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) GB (Completed) FR (Completed) LV (Completed) NL (Completed) SI (Completed)
    Trial results: View results
    EudraCT Number: 2010-018566-23 Sponsor Protocol Number: EORTCprotocol08092 Start Date*: 2011-05-17
    Sponsor Name:European Organisation for Research and Treatment of Cancer
    Full Title: Double blind randomized phase III study of maintenance Pazopanib versus placebo in NSCLC patients non progressive after first line chemotherapy. MAPPING, an EORTC Lung group study.
    Medical condition: Non Small Cell Lung Cancer patients non progressive after first line chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) NL (Prematurely Ended) DE (Prematurely Ended) GB (Prematurely Ended) GR (Prematurely Ended) SI (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-002187-40 Sponsor Protocol Number: GS-LHON-CLIN-05 Start Date*: 2018-03-15
    Sponsor Name:GENSIGHT BIOLOGICS
    Full Title: Efficacy and Safety of Bilateral Intravitreal Injection of GS010: A Randomized, Double-Masked, Placebo-Controlled Trial in Subjects Affected with G11778A ND4 Leber Hereditary Optic Neuropathy for U...
    Medical condition: Leber Hereditary Optic Neuropathy due to mutations in the mitochondrial NADH Dehydrogenase 4 gene
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) FR (Completed) GB (GB - no longer in EU/EEA) ES (Ongoing) NL (Ongoing) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-002359-39 Sponsor Protocol Number: 213406 Start Date*: 2020-09-18
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A PHASE 1, MULTICENTRE, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION STUDY OF NIRAPARIB AND DOSTARLIMAB IN PAEDIATRIC PATIENTS WITH RECURRENT OR REFRACTORY SOLID TUMOURS
    Medical condition: Recurrent or refractory solid tumour
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065147 Malignant solid tumor LLT
    21.1 100000004864 10065252 Solid tumor LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing) GB (GB - no longer in EU/EEA) FR (Trial now transitioned) DE (Trial now transitioned) HU (Trial now transitioned) CZ (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-000189-41 Sponsor Protocol Number: 1368-0024 Start Date*: 2020-07-08
    Sponsor Name:Boehringer Ingelheim RCV GmbH & Co KG
    Full Title: An open-label, single arm, long term trial of Spesolimab treatment in patients with Palmoplantar Pustulosis (PPP) who have completed previous BI Spesolimab trials
    Medical condition: Palmoplantar Pustulosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10040785 - Skin and subcutaneous tissue disorders 10050185 Palmoplantar pustulosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) BE (Completed) FR (Prematurely Ended) PL (Completed) CZ (Completed) GB (GB - no longer in EU/EEA) DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-002989-12 Sponsor Protocol Number: IMR-BTL-201 Start Date*: 2020-06-02
    Sponsor Name:IMARA, Inc.
    Full Title: A Phase 2 Study to Evaluate the Safety and Tolerability of IMR-687 in Subjects with Beta Thalassemia
    Medical condition: β-thalassemia
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004850 10054660 Thalassemia beta LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DK (Prematurely Ended) NL (Prematurely Ended) FR (Prematurely Ended) GR (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 409  410  411  412  413  414  415  416  417  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Feb 16 07:10:17 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA